Alto Neuroscience raises ~$93.9M in registered direct offering of 3.78M shares at $26.48/share

Alto Neuroscience, Inc.

Offering of 3,776,436 shares of common stock at $26.48 per share, expected to close July 14, 2026.
Net proceeds estimated at $93.9M after underwriting discounts and expenses.
Proceeds to accelerate clinical development of ALTO-207, including additional Phase 3 trial for treatment-resistant depression.
Joint book-runners: BofA Securities, Stifel, William Blair, Robert W. Baird; co-managers: JonesTrading, H.C. Wainwright.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.